Deep Learning for Early Identification of Neurodegenerative Diseases

By: Poojitha Nagishetti, Department of Computer Science and Engineering (Data Science), Student of Computer Science and Engineering (Data Science), Madanapalle Institute of Technology and Science, Angallu,517325, Andhra Pradesh.

Abstract ­–

Alzheimer’s, Parkinson’s, and Huntington’s diseases which are neurodegenerative in nature are some of the worst diseases to diagnose because of the progressive nature of their manifestation. The deep learning (DL) methods provide potential solutions of early detection by dealing with the high-dimensional neuroimaging & clinical data. This article gives information on the identification of these diseases by applying the DL techniques such as CNNs RNNs, and Autoencoders. Here, we present current applications of MDS, the most frequently used data sources, the preprocessing of the latter, and the problems encountered. Concerning future directions, work will continue the incorporation of multi-modal data and the improvement of interpretability of the models for better early detection and, therefore, overall patient outcomes.

Keywords – Deep Learning, Neuroimaging, Neurodegenerative Diseases, Model Evaluation, Feature Extraction

Introduction –

Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases belong to one of the most significant world-wide concerns as they are progressive diseases and the difficulties in early diagnosis make them even more serious conditions. These diseases are said to be consequently progressive neuro- de generative diseases that cause substantial impairments in cognitive, motor and functional domains. Once again, early detection is a major concern to improve the chances of treatment and management of the disease since early identification leads to the deceleration of the disease process.

Conventional diagnostic approach of neurodegenerative diseases is mainly clinical that is supported by neuroimaging. Whereas tools such as MRI scanners and computers with PET scans, give essential information, they do not probe with great sensitivity sufficiently to capture earlier changes that precipitate clinical signs. For this reason, there is a slowly growing demand for better diagnostic technologies that can identify the disease in an earlier stage.

AI is a broad term and encompasses many methodologies but the one winning the hearts in the diagnosis of diseases is known as DL[1]. Neural network-based DL algorithms are rather flexible to work on huge and intricate data and able to identify anomalies that are not possible with other techniques[2]. Information collected through micro- and macrostructure analyses of neuroimages, and clinical tests is intended to increase the ability to identify early signs of the disease and, therefore, improve the diagnostic performance of approaches based on DL techniques.

This article focuses on the use of deep learning for early time prediction of neurodegenerative diseases. We will also discuss Techniques such as CNN, RNN, Autoencoder and how the DL approaches are helpful for analyzing neuroimaging and clinical data. Moreover, we will describe the types of obstacles and drawbacks related to these approaches and reflect on other research trends and potentials of development in the field of gender-nonbinary languages. In these aspects, deep learning has every possibility of remodeling early diagnosis of neurodegenerative diseases and also the health results of the patients.

Overview of Neurodegenerative Diseases –

Neurodegenerative diseases are a broad category of diseases contributing to gradual loss of the structure and/or function of the neurons in the brain and/or spinal cord[3]. These diseases are identified by the degeneration of neurons and the synapses establishing their connection to other neural elements in particular areas of the brain at the center of such diseases; these losses contribute to altered functionality of the neurons and are reflected in the symptoms exhibited by the individuals suffering from such diseases.

Alzheimer’s Disease (AD) is a common dementia that is mainly characterized by progressive nature of memory and cognitive deterioration. This is marked by the presence of amyloid-beta plaques and tau protein tangles in this area of the brain hence inhibiting communication at the neuronal level and leading to the death of brain cells. This illness then leads to severe deficits in memory, abstract thinking, and practical judgment and skills; there is yet no remedy for it. Interventions are rather intended to reduce the rate of disease progression and cope with symptoms.

Parkinson’s Disease (PD) mainly involves motor system control and can be defined in terms of tremor, rigidity, bradykinesia or akinesia, and postural instability. This condition is caused by the gradual degeneration of the neurons that produce dopamine in the substantia nigra, which is responsible for the co-ordination of movements. Although we have drugs and operations that can treat the signs, there are no remedies that can cure the disease.

Huntington’s Disease (HD) is defined as a neurodegenerative, autosomal dominant disorder that results in the progressive loss of motor control, as well as changes in cognition and behavior. It is an autosomal dominant disorder that arises from mutation of the HTT gene, and this in turn produces huntingtin protein that has lethal impact on neurons. The manifesting symptoms are such as chorea, impairment in cognitive function, and affective disorder. HD is an on-going, lifelong disease and, although drugs are available which can help to alleviate symptoms, there is yet no cure for the condition.

The processes of development of these diseases are progressive, which complicates the early diagnosis and treatment. Early diagnosis of these conditions is imperative because then the onset of these diseases is treated with greater success and may even halt the development of some of the symptoms. To this day, no cure has been found and thus proper diagnosis and continued research of better treatments is paramount in the quality of life and prognosis of patients with the diseases. Figure 1 explains the workflow diagram outlines the typical steps involved in developing a deep learning model for detecting neurodegenerative diseases, from initial data collection to final model evaluation and publication.

.

Deep Learning Techniques in Neurodegenerative Disease Detection –

In the diagnosis of neurodegenerative diseases, deep learning has significantly improved using more enhanced algorithms resulting in improved analysis of data. The most common of these methods is the Convolutional Neural Networks (CNNs) that is said to be efficient for mediating MRI and PET scans, among others. CNNs are capable of learning as well as extracting useful features from such images, which allows them to detect minuscule brain changes that are associated with neurodegenerative disorders such as AD, PD, HD, amongst others. For example, CNNs can identify atrophy patterns in the structures of the brain, dopamine level, and the alterations of volumes – all of which are very vital at the initial stage of diagnosis.

RNNs, particularly LSTMs are used as the models for analysis of data sequences inclining cognitive test scores or motor function tests that are taken over time[4]. RNNs are capable of learning time dependencies and thus enable the modeling of the process of neurodegenerative diseases predicting the future deterioration of cognitive or motor function based on past data. This capability is crucial to know how these diseases progress and for giving a heads up of worsening condition.

Autoencoders are another key Deep Learning method also used for feature extraction and for dimensionality reduction. They operate by transforming the high number of data points, as for instance neuroimaging scans or clinical measurements, to a lower-dimensional space while retaining salient characteristics[5]. This process is beneficent for the augmentation of performance of follow up classification models by minimizing noise and avoiding redundancy. Autoencoders are mostly useful in preprocessing the data that is fed into other forms of deep learning models hence can help in increasing accuracy of the models and their ability to handle noise.

Altogether these deep learning techniques enhance neurodegenerative diseases prognosis and diagnosis at an early stage. Through the incorporation of these elaborate techniques, both researchers and clinicians are in a better position to understand the underlying pathology of a disease, track disease progression in patients, and accordingly ensure that patients’ outcomes are optimized. Table 1 provides a concise comparison of different neuroimaging modalities based on their strengths, limitations, and typical use cases, which is valuable for understanding their roles in detecting neurodegenerative diseases.

Table 1: Comparison of Neuroimaging Modalities.

Modality	Strengths	Limitations	Typical Use Cases
MRI	High resolution; good for structural imaging	Expensive; limited availability in some areas	Structural brain imaging; tumor detection
PET	Provides metabolic information; detects early changes	Invasive; uses radioactive tracers	Brain function studies; Alzheimer’s detection
CT	Fast; widely available; good for acute conditions	Lower resolution; higher radiation dose	Emergency imaging; trauma assessment
fMRI	Measures brain activity based on blood flow	Sensitive to motion artifacts; lower spatial resolution	Functional brain mapping; cognitive studies

Data Sources and preprocessing –

Data collection, selection, and data preprocessing are main issues when it comes to the utilization of deep learning for the diagnosis of neurodegenerative diseases. Some examples of primary data sources are the MRI and PET scans of the brain which give out the structural and working of the brain[6]. Patients’ data coming from clinical practice, for instance, cognitive scores, as well as other genetic markers, are also informative for predicting disease course and potential factors contributing to the progression of pathology. Several procedures are deemed necessary to prepare these data for analysis, one way or the other. When dealing with imaging data, standardization procedures are employed to bring image intensity values into a common range as well as to spatially register data from different sources or from the same source but acquired at different time points and with different techniques. Some methods like rotation and scaling in the data preparation process alleviate the problem of overfitting by getting additional variants of the training data. Here clinical feature and normalization techniques are used to bring test scores or genetic data into range that is acceptable for deep learning models. Preprocessing minimizes the impact of noise in the data fed to the deep learning algorithms hence improves the accuracy of the models as well as improving the representation of data that exhibit patterns of neurodegenerative diseases.

Challenges and limitations –

It should however be noted that there is still some drawbacks and limitation to the use of deep learning in neurodegenerative disease detection. One such important question is the quality as well as quantity of data, often the neuroimaging datasets are skewed, the number of samples in high stage occurrence is comparatively less than that of early or moderate stage. However, there is a problem of confidentiality as has been seen with the number of patients that have to be prescribed; the information must be well protected hence the ethical standards that have to be upheld. The first serious issue raised by the high-capacity architectures of deep learning models is that they are often ‘black-box’, which means that clinicians cannot fully understand the model making of a particular decision[7]. Another drawback of the AI models trained for a given data sets and tends to overtrain may not easily transferable to other population and different imaging techniques thereby hampering its use in other clinical practice. Also, it is demonstrated that the use of multimodal data, that is, the combination of imaging, genetic, and clinical information while studying MS and aiming at diagnosing the disease is a perspective topic, nevertheless, it is raises several questions regarding data matching and analysis. The solution to all these problems is fundamental in increasing the reliability, and the real-time applicability of deep learning techniques in identifying neurodegenerative diseases.

Future Directions –

Possible developments of early neurodegenerative disorders detection using deep learning in the nearest future are outlined in several directions to increase the diagnostic performances. Using multiple modalities of data for instance, neuroimaging, genetic, and clinical data results in a better understanding of disease processes and the improvement of the model[8]. Improvements in model interpretability are crucial to increase the reliability and credibility of deep learning models for indeed for clinical application so that clinicians can decipher the rationale behind the model’s decisions. Future work could also build upon reinforcement learning and transfer learning to improve the transferability of models to different datasets and populations[9]. Further, it is possible to develop the real-time monitoring and forecasting of the diseases’ development to provide an extremely effective approach to intervening. Last but not the least, the issues of data privacy and ethical characteristics of these technologies should be solved by strict rules of data control and protection as these technologies are going to be used in clinical work. All these collectively provide the promise to enhance the early diagnosis, approach to managing neurodegenerative diseases, and survival of the patients.

Conclusion –

Consequently, the deep learning is the revolutionary method for the early diagnosis and treatment of neurodegenerative diseases. Hoping on the boosted consumption of neuroimaging and clinical information, the possibilities of using deep learning methods such as CNNs, RNNs, and Autoencoders include the ability to diagnose fatal diseases like Alzheimer’s, Parkinson’s, and Huntington’s diseases at an early stage. Nevertheless, there are limitations: of enrolment quality, the interpretability of the obtained results of the modelling, and the overall transferability of the results. Future research is therefore well poised to answer the question through the realistic integration of multi modal data, improved explanation of the models and the actual development of a system- that monitors them. Future growth in these sectors is anticipated to take improved diagnostic precision and effective beginning of treatment for persons diagnosed with neurodegenerative diseases to increase patient care.

References –

1. M. Rahaman, C.-Y. Lin, and M. Moslehpour, “SAPD: Secure Authentication Protocol Development for Smart Healthcare Management Using IoT,” in 2023 IEEE 12th Global Conference on Consumer Electronics (GCCE), Oct. 2023, pp. 1014–1018. doi: 10.1109/GCCE59613.2023.10315475.
2. M. Moslehpour, S. Lewi, D. Kurniawati, T. Ismail, and Y. T. Negash, “The Influence of Social Media Marketing on Voter’s Intention in Indonesia,” in 2021 7th International Conference on E-Business and Applications, in ICEBA 2021. New York, NY, USA: Association for Computing Machinery, Jun. 2021, pp. 212–218. doi: 10.1145/3457640.3457660.
3. H. Fu, J. Hardy, and K. E. Duff, “Selective vulnerability in neurodegenerative diseases,” Nat. Neurosci., vol. 21, no. 10, pp. 1350–1358, Oct. 2018, doi: 10.1038/s41593-018-0221-2.
4. J. Lang, M. A. Giese, M. Synofzik, W. Ilg, and S. Otte, “Early Recognition of Ball Catching Success in Clinical Trials with RNN-Based Predictive Classification,” in Artificial Neural Networks and Machine Learning – ICANN 2021, I. Farkaš, P. Masulli, S. Otte, and S. Wermter, Eds., Cham: Springer International Publishing, 2021, pp. 444–456. doi: 10.1007/978-3-030-86380-7_36.
5. J. Zabalza et al., “Novel segmented stacked autoencoder for effective dimensionality reduction and feature extraction in hyperspectral imaging,” Neurocomputing, vol. 185, pp. 1–10, Apr. 2016, doi: 10.1016/j.neucom.2015.11.044.
6. H. F. Wehrl et al., “Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales,” Nat. Med., vol. 19, no. 9, pp. 1184–1189, Sep. 2013, doi: 10.1038/nm.3290.
7. M. Alzantot, Y. Sharma, S. Chakraborty, H. Zhang, C.-J. Hsieh, and M. B. Srivastava, “GenAttack: practical black-box attacks with gradient-free optimization,” in Proceedings of the Genetic and Evolutionary Computation Conference, in GECCO ’19. New York, NY, USA: Association for Computing Machinery, Jul. 2019, pp. 1111–1119. doi: 10.1145/3321707.3321749.
8. S. Khanna, D. Domingo-Fernández, A. Iyappan, M. A. Emon, M. Hofmann-Apitius, and H. Fröhlich, “Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Biological Mechanisms,” Sci. Rep., vol. 8, no. 1, p. 11173, Jul. 2018, doi: 10.1038/s41598-018-29433-3.
9. M. Rahaman, B. Chappu, N. Anwar, and P. K. Hadi, “Analysis of Attacks on Private Cloud Computing Services that Implicate Denial of Services (DoS),” vol. 4, 2022.
10. Gupta, B. B., & Narayan, S. (2021). A key-based mutual authentication framework for mobile contactless payment system using authentication server. Journal of Organizational and End User Computing (JOEUC), 33(2), 1-16.
11. Vajrobol, V., Gupta, B. B., & Gaurav, A. (2024). Mutual information based logistic regression for phishing URL detection. Cyber Security and Applications, 2, 100044.
12. Gupta, B. B., Gaurav, A., Panigrahi, P. K., & Arya, V. (2023). Analysis of cutting-edge technologies for enterprise information system and management. Enterprise Information Systems, 17(11), 2197406.

Cite As

Nagishetti P. (2024) Deep Learning for Early Identification of Neurodegenerative Diseases, Insights2Techinfo, pp.1

780500cookie-checkDeep Learning for Early Identification of Neurodegenerative Diseasesyes